Literature DB >> 14654264

Analysis and treatment of different types of neuropathic cancer pain.

Petra Stute1, Jens Soukup, Matthias Menzel, Rainer Sabatowski, Stefan Grond.   

Abstract

Neuropathic pain is a major problem in the treatment of cancer pain. We performed a retrospective analysis of 213 cancer patients with neuropathic pain treated by a pain service following the World Health Organization guidelines for relief of cancer pain. Of these, 79% presented with nerve compression pain, 16% with nerve injury pain, and 5% with sympathetically-maintained pain. Whereas nerve compression and nerve injury pain were caused most frequently by cancer growth, sympathetically-maintained pain was caused most frequently by cancer treatment. There were no significant differences in the use of analgesics, the mean pain intensity, or the efficacy of analgesic treatment among the three groups. Nerve injury pain and sympathetically-maintained pain were treated more frequently with adjuvant analgesics, especially antidepressants and anticonvulsants. The variety of different neuropathic pain syndromes should be separated in future studies of the efficacy of different treatment approaches.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14654264     DOI: 10.1016/j.jpainsymman.2003.04.002

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  11 in total

1.  Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study.

Authors:  Daniel Arbaiza; Oscar Vidal
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 2.  Managing difficult pain conditions in the cancer patient.

Authors:  Sebastiano Mercadante
Journal:  Curr Pain Headache Rep       Date:  2014-02

3.  Neuropathic pain referrals to a multidisciplinary pediatric cancer pain service.

Authors:  Doralina L Anghelescu; Lane G Faughnan; Mark P Popenhagen; Linda L Oakes; Deqing Pei; Laura L Burgoyne
Journal:  Pain Manag Nurs       Date:  2012-08-25       Impact factor: 1.929

4.  Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health.

Authors:  Ana Mańas; Juan Pablo Ciria; María Carmen Fernández; María Luisa Gonzálvez; Virginia Morillo; María Pérez; Xavier Masramon; Vanessa López-Gómez
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

5.  Lidocaine 5 % patches as an effective short-term co-analgesic in cancer pain. Preliminary results.

Authors:  Cristina Garzón-Rodríguez; Miquel Casals Merchan; Agnes Calsina-Berna; Eugenia López-Rómboli; Josep Porta-Sales
Journal:  Support Care Cancer       Date:  2013-09-03       Impact factor: 3.603

6.  Development of a novel location-based assessment of sensory symptoms in cancer patients: preliminary reliability and validity assessment.

Authors:  Adam R Burkey; Peter A Kanetsky
Journal:  J Pain Symptom Manage       Date:  2008-12-06       Impact factor: 3.612

7.  [Regulation of spinal nociceptin expression by neuropathic pain].

Authors:  A Gabriel; C Pietruck; T Meuser; M Sharma; P Pierce Palmer; S Grond
Journal:  Anaesthesist       Date:  2004-07       Impact factor: 1.041

Review 8.  The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it?

Authors:  Karine Azevedo São Leão Ferreira; Miako Kimura; Manoel Jacobsen Teixeira
Journal:  Support Care Cancer       Date:  2006-06-08       Impact factor: 3.359

9.  Clinical management of pain in advanced lung cancer.

Authors:  Claribel P L Simmons; Nicholas Macleod; Barry J A Laird
Journal:  Clin Med Insights Oncol       Date:  2012-10-08

10.  Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting.

Authors:  Emilio Blanco Tarrio; Rafael Gálvez Mateos; Enric Zamorano Bayarri; Vanessa López Gómez; Maria Pérez Páramo
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.